24 results
8-K
EX-99.1
LUMO
Lumos Pharma Inc
15 Nov 23
Other Events
4:38pm
on treatment Investigational product safety profile remains clean after1,300 patients treated to date1 Phase 2 results support advancing to Phase 3
8-K
EX-99.2
LUMO
Lumos Pharma Inc
7 Nov 23
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD
4:08pm
normalizes IGF-1 SDS within 6 months on treatment Investigational product safety profile remains clean after1,300 patients treated to date1 Phase
10-K
xtnqib67wokkhlbchl
30 Mar 12
Annual report
12:00am